Indian Immunologicals Disputes Abhayrab Findings, Submits Records

When substandard product allegations surface in the field, the speed and completeness of a manufacturer's documentary response to regulators often determines how the investigation unfolds. Indian Immunologicals Limited (IIL) is now navigating that dynamic directly, after denying responsibility for low-quality Abhayrab (rabies vaccine) vials identified in Delhi and formally requesting an independent probe into their origin.

IIL submitted its manufacturing, quality-control, reconciliation, and distribution records to CDSCO on 14 August 2026, positioning the documentation package as evidence that the flagged vials were not produced at its facility. The company's public denial is paired with an active call for regulatory investigation, a posture that signals confidence in its batch traceability infrastructure while placing the evidentiary burden on the supply chain between its dispatch point and the Delhi market.

For QA directors managing post-market surveillance programmes, the case underscores a compliance reality embedded in 21 CFR Part 211 and its Indian GMP equivalents: reconciliation records and distribution logs are not administrative formalities. They are the primary defence instrument when a product complaint escalates to a regulatory inquiry. IIL's ability to produce those records promptly to CDSCO reflects the kind of real-time batch disposition readiness that Schedule M and WHO GMP guidelines expect of vaccine manufacturers.

The broader supply-chain read is that substandard or falsified product entering a distribution network can implicate the originating manufacturer regardless of actual fault, particularly when serialisation and cold-chain verification data are incomplete downstream. Regulatory affairs leads monitoring CDSCO's handling of this case should note that the agency's investigative response, and any subsequent market action, will likely hinge on cross-referencing IIL's submitted records against distributor and retailer documentation in Delhi.

The outcome of CDSCO's investigation will set a visible precedent for how batch traceability evidence is weighted against field-sample test results in post-market enforcement decisions.

Source: Indian Pharma Post via Media4Growth, 6 September 2026.